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Reply to Niermeijer
To the Editor:
We thank Prof. Niermeijer for his response to and com-
ments on our letter to the editor, regarding health, life,
and disability insurance in hereditary nonpolyposis co-
lorectal cancer (HNPCC). As stated in our letter, our
survey respondents probably represented !5% of insur-
ance policies sold in the United States. We agree with
Prof. Niermeijer that “the silence of the majority of the
insurance companies in the U.S. study by Rodriguez-
Bigas et al. (1998) reflects the general neglect of this
subject in discussions between governments of the major
economic countries and the regulators of the insurance
and underwriter’s system.” However, we were encour-
aged to find, as stated in our earlier letter, that “the
majority of health, life, and disability insurance provid-
ers with an opinion would be willing to sell insurance
to HNPCC gene carriers and at risk-individuals” (Rod-
riguez-Bigas et al. 1998, p. 737). This apparent dichot-
omy in our survey reflects the need for legislative bodies,
insurance providers, health-care providers (including ge-
neticists and counselors), as well as members of affected
kindreds, to enter into dialogues so that further steps
can be taken for public and professional education, as
well as for prevention of genetic discrimination in our
societies.
Similar to what has occurred in the Netherlands, leg-
islative action has been undertaken in the United States,
with regard to potential genetic discrimination. The
Health Insurance Portability and Accountability Act of
1996, which went into effect on July 1, 1997, includes
provisions that deal with genetic discrimination as it
relates to the use of genetic information on individuals
who have or who are eligible for health insurance under
a group health plan offered by an employer. Under this
law, genetic information is included in the list of “health
status-related factors” that an insurer is prohibited from
using to deny, cancel, or refuse to renew insurance cov-
erage. The law also states that genetic information may
not be treated as a preexisting condition, without a di-
agnosis of the condition related to this information. An-
other provision provides that the health status of an
individual or his or her dependents cannot be used to
charge premium rates different from those applied to
other, similarly situated individuals within the group.
Although this law addresses some potential health in-
surance–discrimination concerns, it does not apply to
individuals ineligible for group health-insurance policies.
Furthermore, this law does not restrict the use of indi-
vidual genetic information for the purpose of setting a
particular group premium. These “gaps” in protection
demonstrate that, although legislation such as this has
been enacted, all issues related to potential health-in-
surance discrimination regarding individuals affected
with and/or at risk for genetic conditions such as
HNPCC have yet to be remedied. There is ongoing ac-
tivity, on both the federal and the state levels, to address
these “gaps” and other societal issues associated with
genetic status. In the meantime, it is the policy at our
institution, as it is in many other centers in the United
States and elsewhere, to provide risk assessment and ge-
netic consultation in order to address the exact issues
raised by Prof. Niermeijer.
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